Shots:

• The companies collaborated to evaluate the safety- PK & antiviral activity of ATI-2173- vebicorvir & TDF in an ongoing P-IIa ANTT201 trial in 10 treatment naïve or off-treatment HBeAg negative or positive patients with chronic HBV infection. The cohort is expected to start in H1’22
• ATI-2173 has demonstrated a well-tolerated safety profile & uses an ASPIN mechanism in clinical development for combination therapy. ATI-2173 is currently being evaluated in P-II clinical development
• In P-II trials- vebicorvir was administered with NrtI therapy & demonstrated a favorable safety profile & led to greater viral suppression of HBV DNA & HBV pgRNA over NrtI therapy alone

  | Ref: PR Newswire | Image: Inf.News